quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:18:31·156d
PRRelease
Cellectis S.A. logo

Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

CLLS· Cellectis S.A.
Health Care
Original source

Companies

  • CLLS
    Cellectis S.A.
    Health Care

Recent analyst ratings

  • Feb 17UpdateJefferies$7.00
  • Mar 17UpdateBryan Garnier$6.00
  • May 18UpdateRobert W. Baird$10.00
  • Jan 6UpdateWells Fargo$16.00
  • Nov 30UpdateJMP Securities$20.00
  • Nov 8UpdateWilliam Blair-

Related

  • SEC10d
    SEC Form 6-K filed by Cellectis S.A.
  • PR10d
    Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform
  • SEC42d
    SEC Form 6-K filed by Cellectis S.A.
  • PR42d
    Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
  • ANALYST65d
    Jefferies resumed coverage on Cellectis with a new price target
  • SEC105d
    SEC Form 6-K filed by Cellectis S.A.
  • PR105d
    Cellectis Announces 2026 Strategy and Catalysts
  • PR129d
    Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022